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1 Drug description 
Generic/Brand name/ATC code:  
Idelalisib/Zydelig®/L01XX47 
Developer/Company:  
Gilead Sciences, Inc. 
Description:  
Idelalisib (Zydelig®, GS-1101, CAL-101) is an inhibitor of the delta isoform 
of phosphatidylinositol-3-kinase (PI3K) which is expressed in normal and 
malignant B cells. By integrating and transmitting signals from surface mol-
ecules (e.g. B-cell receptor, cytokine and chemokine receptors, integrin β1) 
PI3K regulates key cellular functions including growth, survival and mi-
gration. Idelalisib inhibits several cell-signalling pathways and thus prolif-
eration and survival, and promotes apoptosis in many B-cell malignancies 
[1, 2]. 
Zydelig® is administered orally, twice daily, at a dosage of 150 mg; the 
treatment should be continued until disease progression (PD) or unaccepta-
ble toxicity occurs [3]. 
 
2 Indication 
Idelalisib (Zydelig®) is indicated in combination with rituximab in adult pa-
tients with chronic lymphocytic leukaemia (CLL) who have received at least 
one prior therapy, or as first-line treatment for patients with deletion 17p 
and/or TP53 mutation who are inappropriate candidates for chemoimmuno-
therapy [3]. 
 
3 Current regulatory status 
After receiving a positive opinion from the Committee for Medicinal Prod-
ucts for Human Use (CHMP) in July 2014 [4], the EMA granted marketing 
authorisation for Zydelig® on 18 September 2014 for the following indica-
tions: 
 in combination with rituximab for the treatment of adult patients 
with CLL who have received at least one prior therapy or as first-
line treatment in the presence of 17p deletion or TP53 mutation in 
patients unsuitable for chemoimmunotherapy, 
 as monotherapy for the treatment of adult patients with follicular 
lymphoma that is refractory to two prior lines of treatment [3]. 
On 23 July 2014, the FDA approved Zydelig® for three types of blood cancer: 
 for relapsed CLL in combination with rituximab (in patients un-
suitable for rituximab monotherapy due to other co-morbidities), 
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 for relapsed follicular B-cell non-Hodgkin lymphoma (in patients 
who have received at least two prior systemic therapies), 
 for relapsed small lymphocytic lymphoma (in patients who have re-
ceived at least two prior systemic therapies). 
The FDA also granted orphan product designation for Zydelig® [5]. 
The Zydelig® prescribing information contains a boxed warning concerning 
potentially occurring fatal and serious toxicities (hepatotoxicity, severe diar-
rhoea, colitis, pneumonitis and intestinal perforation [2]. 
 
4 Burden of disease 
CLL is a B-cell chronic lymphoproliferative disorder causing a progressive ac-
cumulation of functionally incompetent lymphocytes; it is the most common 
leukaemia in adults in Western countries. The incidence is 4.2/100.000 per 
year and increases to > 30/100.000 per year at an age over 80 years [6]. The 
median age at diagnosis is 72 years; older patients often cannot tolerate ag-
gressive therapy regimens due to comorbidities and declining organ function 
[8]. 
Risk factors for CLL are a family history of CLL or other lymph-related can-
cers, older age, gender (men are more often affected than women) [7], ethnici-
ty (CLL is more common in North America and Europe than in Asia) and cer-
tain chemical exposures [8]. 
The majority of CLL cases are diagnosed by routine blood counts showing 
lymphocytosis in otherwise asymptomatic patients. Signs discernible during 
physical examination indicating CLL may include lymphadenopathy, sple-
nomegaly, hepatomegaly or skin lesions [9]. If existing, symptoms range from 
painless swelling of lymph nodes to symptoms corresponding to acquired im-
munodeficiency disorders such as infections or autoimmune complications. 
Only 5–10% of affected patients show the “typical” lymphoma symptoms 
(generally termed “B symptoms”): 
 unintentional weight loss ≥ 10% of body weight within the previous 6 
months,  
 fevers of > 38°C for ≥ 2 weeks without evidence of infection, 
 night sweats without evidence of infection, 
 extreme fatigue.  
Based on the results of physical examination and complete blood count, two 
staging systems are applied: 
 the (modified) Rai staging system, assigning patients to a low risk 
(lymphocytosis), intermediate risk (lymphadenopathy, organomeg-
aly) or high risk (anaemia, thrombocytopenia) group. 
 the Binet staging system, consisting of stage A (< than 3 involved 
lymphoid sites), stage B (≥ 3 involved lymphoid sites) and stage C 
(presence of anaemia and/or thrombocytopenia) [9]. 
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CLL prognosis is influenced by the presence of certain serum markers (thy-
midin-kinase, beta-2 microglobulin), genetic markers (including IGHV muta-
tional status), cytogenetic abnormalities (deletion of 11q, 13q and 17p, CD38 
expression and ZAP-70 expression) and other genetic lesions (including muta-
tions in NOTCH1, SF3B1 and/or BIRK3 genes) [10]. There is evidence that 
some of those factors (17p deletion, 11q deletion, TP53, NOTCH1 and SF3B1 
mutations) may play a role in chemorefractoriness and worse prognosis [11]. 
The presence of those prognostic factors should not be decisive for initiating 
CLL treatment [10]. However, presence of deletion 17p is guiding therapy and 
should be determined before initiation of any line of therapy. Likewise, testing 
for TP53 mutation should be performed before starting treatment. Data from 
the CLL8 trial suggests NOTCH1 mutation as a predictive factor for reduced 
benefit from adding rituximab to chemotherapy and SF3B1 mutation as a 
strong prognostic marker providing information on progression. Both findings 
need to be confirmed by additional clinical trials [12]. 
For asymptomatic patients, there is no need to start with CLL treatment im-
mediately after diagnosis, but observation is the standard of care for those pa-
tients. Therapy is indicated if the following disease-related complications (“ac-
tive disease”) occur: 
 “typical” lymphoma symptoms, 
 Rai stages III or IV, Binet stage C, 
 autoimmune haemolytic anaemia and/or thrombocytopenia poorly 
responsive to corticosteroid therapy. 
 Progressive disease (= increasing lymphocytosis with a lymphocyte 
doubling time less than 6 months and/or rapidly enlarging lymph 
nodes, spleen and liver) [13]. 
 
5 Current treatment 
Various treatment options exist for CLL patients depending on patient 
characteristics such as age or comorbidities and tumour characteristics. De-
pending on the patient’s response to first-line therapy, relapsed or refractory 
disease can be differentiated. Relapsed disease is defined as a progressive 
disease after a period of six months or more after either a complete or par-
tial remission had been achieved [14]. If patients do not respond to thera-
py, i.e. if they fail to achieve either a partial or complete remission with 
therapy, or if they develop a disease progression within six months of ther-
apy, they have refractory disease [15]. 
After first-line therapy, further treatment will depend on the regimen ad-
ministered previously, duration of remission, age and comorbidities. The 
following therapy options exist [1]: 
 Second and subsequent line chemotherapy: 
o Combination therapy with fludarabine, cyclophospha-
mide and rituximab (FCR) if patients can tolerate it or if 
they responded well (PFS > 24 months) to first-line FCR 
[16] or bendamustine and rituximab (well-established, 
but few RCTs).  
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asymptomatic 
patients: 
observation 
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o For older patients or those with comorbidities who are 
not considered well enough for intensive cytotoxic chem-
otherapy (e.g. FCR), there is no recognised standard 
treatment. Options include chlorambucil with rituximab 
(in patients previously untreated with chemotherapy), 
bendamustine (with or without rituximab) or dose-
reduced FCR. 
 Biological therapy: 
o Rituximab may be used in combination with chemother-
apy agents. 
o Other anti-CD20 monoclonal antibodies, such as ofatu-
mumab, may be considered; ofatumumab is currently be-
ing used predominantly in patients who are refractory to 
rituximab and alemtuzumab. 
o Ibrutinib for CLL patients with 17p deletion which is as-
sociated with poor responses to standard treatment of CLL 
(approved by the FDA for this indication in July 2014)[5]. 
o Allogeneic stem-cell transplantation should be consid-
ered for fit patients with high-risk CLL and should ideal-
ly be performed in the setting of a remission. 
o Alemtuzumab and methylprednisolone for patients with 
high-risk disease (with early relapse or TP53 dele-
tion/mutation) when tolerated, or alemtuzumab with or 
without corticosteroids as an option for fitter patients 
who have failed other conventional therapies. However, 
the drug was voluntarily withdrawn by the marketing au-
thorisation holder in Europe in 2012 [17].  
 Radiotherapy: rarely used, may be indicated for patients with en-
larged lymph nodes/spleen or prior to bone marrow transplant [1]. 
 
6 Evidence 
A literature search was conducted in October 2014 in four databases (Med-
line, Embase, CRD Database and The Cochrane Library). Search terms 
were “Idelalisib”, “CAL 101”, “GS 1101” “Chronic lymphocytic leukae-
mia”, “Zydelig”. Also, the manufacturer was contacted for any further evi-
dence, and submitted 2 references (one of them already identified by the 
systematic literature search) and general information about current 
idelalisib trials.  
Overall, 384 references were identified; one phase III trial [18] was includ-
ed in this report. 
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6.1 Efficacy and safety – Phase III studies 
Table 1: Summary of efficacy 
Study title  
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia [18, 19] 
Study  
identifier 
NCT01539512, EudraCT Number 2011-005180-24, Trial protocol ID GS-US-312-0116 
Design Multicentre, randomised, double-blind, placebo-controlled 
Duration  Enrolment: May 2012–August 2013 
Median follow-up: NR 
Data cut-off dates for analyses:  2013-08-30 (first interim 
analysis), 2013-10-09 (second interim analysis) 
Hypothesis Superiority  
The sample size provided a power of more than 85% to detect a 75% improvement in 
the median PFS. Two interim analyses were pre-specified after approximately 50% and 
75% of the anticipated 119 events had occurred, at alpha levels of 0.001 and 0.005, 
respectively. 
Funding Gilead Sciences, Inc. 
Treatment 
groups 
Intervention 
(n=110) 
Idelalisib 150 mg (oral) twice daily +  
rituximab intravenously at a dose of 375 mg per square metre of 
body-surface area, followed by 500 mg per square metre every 2 
weeks for 4 doses and then every 4 weeks for 3 doses (for a total 
of 8 infusions) 
Control 
(n=110) 
Placebo (oral) twice daily + 
rituximab intravenously at a dose of 375 mg per square metre of 
body-surface area, followed by 500 mg per square metre every 2 
weeks for 4 doses and then every 4 weeks for 3 doses (for a total 
of 8 infusions) 
Endpoints 
and 
definitions 
Progression-free 
survival 
(primary outcome) 
PFS Interval from randomisation to disease progression or 
death from any cause 
Overall survival OS Interval from randomisation to death from any cause 
Rate of overall 
response 
ORR Proportion of patients who had a complete or partial 
response on the basis of the IWCLL modified criteria 
Lymph-node 
response rate 
- Proportion of patients who had a decrease of 50% or 
more in lymphadenopathy 
Results and analysis 
Analysis  
description 
 
 
 
 
Intention-to-treat analysis 
PFS calculated by using the Kaplan-Meier method, rates compared by using a stratified 
log-rank test 
Hazard ratios calculated by using a Cox model with adjustment for stratification 
For binary-response end points the Cochran-Mantel-Haenszel chi-square test, adjusted 
for stratification, was used 
Analysis  
population 
Inclusion  CLL that had progressed within 24 months after the last 
treatment 
 Patients unable to receive cytotoxic agents for one or more of 
the following reasons: 
- Severe neutropenia or thrombocytopenia caused by 
cumulative myelotoxicity from previous therapies 
- An estimated creatinine clearance of less than 60 ml per 
minute 
- A score on the CIRS of more than 6 for coexisting illnesses 
not related to CLL 
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 Previous treatment must have included either a CD20 antibody-
based regimen or at least two previous cytotoxic regimens 
Exclusion  Known histological transformation from CLL to an aggressive 
lymphoma 
 Presence of intermediate- or high-grade myelodysplastic 
syndrome  
Characteristics  Intervention Control 
 Gender, male, % 69 62 
Median age (range), years 71 (48–90) 71 (47–92) 
Rai stage, % of patients 
  0 
  1 or 2  
  3 or 4 
  Missing data 
 
0 
31 
64 
5 
 
1 
26 
65 
7 
Extent of CLL, % of patients 
  Anaemia: any grade/grade ≥3 
  Neutropenia: any grade/grade ≥3 
  Thrombocytopenia: any grade/ 
grade ≥3 
 
75/6 
34/17 
62/16 
 
72/11 
35/16 
61/29 
Median absolute lymphocyte count, 
per mm3 
31,960 30,880 
Median estimated creatinine 
clearance, ml/min 
62 67 
  Genetic stratification factors, % of  
  patients  
  Unmutated IGHV 
  17p deletion or  
  TP53 mutation 
 
 
83 
42 
 
 
85 
45 
Median CIRS score 8 8 
Previous CLL treatment  
- median number of drugs 
(range) 
- Drugs, % of patients 
o Rituximab 
o Cyclophosphamide 
o Fludarabine 
o Bendamustine 
o Chlorambucil 
 
3 (1–12) 
 
91 
64 
56 
58 
31 
 
 
3 (1–9) 
 
88 
70 
64 
54 
22 
 
Descriptive 
statistics 
and 
estimated 
variability 
Treatment group Idelalisib + rituximab Placebo + rituximab 
Number of subjects N=110 N=110 
Median PFS, months  NR 5.5 
PFS at 24 weeks, % 93  46 
Median OS, months NR NR 
OS at 12 months, %  92 80 
ORR, %                  81 13 
Lymph node response, 
reduction rate, % 
93 4 
Effect 
estimate per 
comparison 
 Comparison groups  Intervention vs. Control 
PFS (August 2013) HR 0.15 
95% CI 0.08–0.28 
P value  <0.001 
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PFS (October 2013) [19] HR 0.18 
95% CI 0.10–0.32 
P value  <0.001 
OS (August 2013) HR 0.28 
95% CI 0.09–0.86 
P value  0.02 
OS (October 2013) HR 0.28 
95% CI 0.11–0.69 
P value  0.003 
ORR Odds ratio 29.92 
95% CI NA 
P value   <0.001 
Lymph node response Odds ratio 264 
Variability - 
P value  <0.001 
Abbreviations: CI = confidence interval, CIRS = Cumulative Illness Rating Scale (ranges from 0 to 56, with higher scores indi-
cating an increased number or greater severity of coexisting illness), CLL = chronic lymphocytic leukaemia, IWCLL = Interna-
tional Workshop on Chronic Lymphocytic Leukaemia, NA = not available, NR = not reached, Rai = system for staging CLL 
(0=low-risk disease, 1–2=intermediate risk, 3–4=high risk), ORR = overall response rate, OS = overall survival, PFS = pro-
gression-free survival 
Table 2: Most frequent adverse events 
NCT01539512 
Adverse Event 
(according to NCI-
CTCAE version 4.03) 
Idelalisib + rituximab (N=110) Placebo + rituximab (N=107) 
Any grade 
n (%) 
Grade ≥3 
n (%) 
Any grade 
n (%) 
Grade ≥3 
n (%) 
AEs during treatment 100 (91) 62 (56) 101 (94) 51 (48) 
Pyrexia 32 (29) 3 (3) 17 (16) 1 (1) 
Fatigue 26 (24) 3 (3) 29 (27) 2 (2) 
Nausea 26 (24) 0 23 (21) 0 
Chills 24 (22) 2 (2) 17 (16) 0 
Diarrhoea 21 (19) 4 (4) 15 (14) 0 
Infusion-related 
reaction 
17 (15) 0 30 (28) 4 (4) 
Cough 16 (15) 0 27 (25) 2 (2) 
Constipation 13 (12) 0 12 (11) 0 
Decreased appetite 13 (12) 0 9 (8) 1 (1) 
Vomiting 13 (12) 0 8 (7) 0 
Dyspnoea 12 (11) 2 (2) 20 (19) 3 (3) 
Night sweats 11 (10) 0 8 (7) 0 
Rash 11 (10) 2 (2) 6 (6) 0 
Serious AEs 44 (40) NA 37 (35) NA 
Discontinuation due 
to AEs, % 
9 (8) 11  (10) 
Abbreviations: AE = adverse event, NCI = National Cancer Institute, CTCAE = Common Terminology Criteria for Adverse 
Events, NA = not applicable (serious adverse events are reported as severe regardless of the severity grading) 
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This multicentre, randomised, double-blind, placebo-controlled phase III 
study [18] evaluated the efficacy and safety of idelalisib combined with 
rituximab compared to placebo plus rituximab. A total of 220 CLL patients 
were included, all of whom had progressed within 24 months after the last 
therapy. Prior administered treatment must have included at least two pre-
vious cytotoxic regimens or a CD20 antibody-based regimen. The median 
number of prior drugs was 3; applied regimens were rituximab, cyclophos-
phamide, fludarabine, bendamustine and chlorambucil. All patients were 
ineligible for cytotoxic therapy due to different reasons: severe neutropenia 
or thrombocytopenia, an estimated creatinine clearance of less than 60 ml 
per minute or a CIRS score of more than 6. The median age of patients in 
both groups was 71 years, 64% (idelalisib group) and 65% (placebo group) of 
patients were assigned to Rai stage 3 or 4. Median CIRS score was 8 in both 
groups. 83% (idelalisib group) and 85% of patients (placebo group) had an 
unmutated IGHV status, and 42% (idelalisib group) and 45% (placebo 
group) of patients showed 17p deletion or TP53 mutation.  
At the beginning of study treatment, all patients received rituximab intrave-
nously. After stratification according to genetic factors (unmutated IGHV, 
17p deletion or TP53 mutation), the patients were randomly assigned to two 
treatment arms: the idelalisib group (receiving idelalisib at a dosage of 150 
mg twice daily plus rituximab) and the placebo group (receiving placebo 
plus rituximab). The median duration of treatment was 3.8 months in the 
idelalisib group versus 2.9 months in the placebo group. 
The primary end point of the study was PFS; secondary endpoints were the 
rates of overall and complete response, lymph node response and overall 
survival. Furthermore, the idelalisib-associated lymphocytosis was a meas-
ured value. 
After 24 weeks of treatment, the rate of PFS was 93% in the idelalisib group 
compared to 46% in the placebo group. The median PFS was 5.5 months in 
the placebo group and was not reached by the idelalisib group (HR 0.15, 
95% CI 0.08–0.28, p<0.001). After the second interim analysis in October 
2013, the results remained the same [19]. The positive effect of idelalisib and 
rituximab was observed in all pre-specified subgroups as well, regardless of 
the presence or absence of genetic factors. 
The OS rate at 12 months was 92% in the idelalisib group versus 80% in the 
placebo group, with an adjusted HR for death of 0.28 (95% CI 0.09–0.86, 
p=0.02); 4% (idelalisib group) and 11% (placebo group) of study patients 
died while participating. The ORR (all partial responses) was 81% in the 
idelalisib group compared to 13% in the placebo group. Analysis of post-
baseline conducted imaging procedures showed a significant higher reduc-
tion of 50% or more in lymphadenopathy in the idelalisib group than in the 
placebo group. 
Lymphocyte count showed a peak at week 2 and resolved by week 12 in the 
idelalisib group, while starting to increase at week 24 (after rituximab ad-
ministration ended) in the placebo group. 
In the highest-risk patients, who were positive for both 17p deletion and 
TP53 mutation, the combination therapy achieved 76.5% ORR and PFS HR 
0.13 [20].  
a phase III trial 
compared efficacy 
and safety of 
idelalisib + rituximab 
to placebo + 
rituximab in 220 
patients 
median PFS was 5.5 
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improved rates of OS 
and overall response 
in the idelalisib 
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At least one adverse event (AE) occurred in 90% of patients in each treat-
ment group, but most of them were grade 2 or lower. The most common AEs 
in the idelalisib group were pyrexia, fatigue, nausea, chills and diarrhoea; in 
the placebo group infusion-related reactions, fatigue, cough, nausea and 
dyspnoea were most frequent. 40% (idelalisib group) and 35% (placebo 
group) of patients had at least one serious AE: pneumonia, pyrexia and fe-
brile neutropenia were most common. Laboratory abnormalities more fre-
quent in the idelalisib group compared to the placebo group were ALT (ala-
nine aminotransferase) or AST (aspartate aminotransferase) elevation (35% 
vs. 19%) and neutropenia (55% vs. 49%). 
8% of patients in the idelalisib group and 10% of patients in the placebo 
group discontinued study treatment due to AEs. Most commonly, disease 
progression was causal for discontinuing study treatment.  
The statistically significant improvement in the rate of PFS was the decid-
ing factor to terminate the study after the first pre-specified interim ana-
lysis. Patients who had disease progression during placebo treatment could 
receive idelalisib in an extension study (NCT01539291, estimated study 
completion date is December 2015). For patients who had disease progres-
sion despite receiving idelalisib, the administration of an increased dose 
(300 mg twice a day) was provided. 
Additionally, health-related quality-of-life (HRQL) was evaluated among 
the two treatment arms. The 44-item Functional Assessment of Cancer 
Therapy-Leukemia scale (FACT-Leu) was used for this purpose, measuring 
physical, functional, social and emotional well-being as well as leukaemia-
specific concerns. [21]. Compared to the control arm, idelalisib-receiving pa-
tients showed statistically significant and clinically meaningful improve-
ments in HRQL FACT-Leu measurements [19]. These results were only 
published in an abstract. 
 
6.2 Efficacy and safety – further studies 
No phase II studies that fit the purpose of this assessment were identified.  
 
7 Estimated costs 
One package Zydelig® containing 60 tablets at 150 mg costs € 4,395.50 [22]. 
Assuming that two 500 mg MabThera® infusions are needed for each rituxi-
mab infusion, costs for the regimen used in the study (150 mg idelalisib 
twice daily + 8 infusions rituximab) would amount to about € 47,190 for 5 
months or to € 9,440 per month. Continuation of Zydelig® therapy and the 
treatment of side effects are not included.  
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8 Ongoing research 
In October 2014, a search in databases www.clinicaltrials.gov and 
www.clinicaltrialsregister.eu was conducted; the following trials were identi-
fied: 
 NCT01539291 (EudraCT number: 2011-006293-72): a multicentre, 
2-arm, double-blind, parallel-group extension study (phase III) 
aims to evaluate the effect of idelalisib on the onset, magnitude and 
duration of tumour control. It is a companion study for patients 
with CLL who participated in study GS-US-312-0116. Estimated 
study completion date is December 2015. 
 NCT02136511 (EudraCT number: 2013-005343-82): an expanded 
access study (idelalisib in combination with rituximab) for previ-
ously treated patients with relapsed CLL.  
Ongoing phase III trials evaluating idelalisib combination therapies:  
 NCT01569295 (EudraCT number: 2011-006292-20): a phase III, 
randomised, double-blind, placebo-controlled study assessing the 
effect of idelalisib in combination with bendamustine and rituxi-
mab for previously treated CLL. Estimated study completion date 
is December 2017. 
 NCT01659021 (EudraCT number: 2012-001236-65): this random-
ised, controlled phase III study evaluates the efficacy and safety of 
idelalisib in combination with ofatumumab in previously treated 
patients with CLL. Estimated study completion date is November 
2016. 
There are several phase I and phase II studies ongoing, assessing the effect 
of idelalisib on relapsed CLL as a single agent or in combination with other 
drugs. Furthermore, different trials evaluate the efficacy of idelalisib on 
other types of cancer, including SLL, indolent non-Hodgkin lymphomas, 
follicular lymphomas or multiple myeloma. 
 
9 Commentary 
Idelalisib (Zydelig®) affects CLL cell functions by targeting the B-cell recep-
tor signalling pathway. It has been approved by the EMA in September 
2014; the FDA granted marketing authorisation in July 2014. Idelalisib is 
indicated in adult patients with CLL who have received at least one prior 
therapy and as first-line regimen for patients with 17p deletion or TP53 mu-
tation status who are unsuitable for chemoimmunotherapy [2, 3].  
These decisions were based on a phase III trial assessing idelalisib with 
rituximab in comparison to placebo with rituximab in 220 patients. All pa-
tients had been previously treated and were considered ineligible for (fur-
ther) cytotoxic therapy [18].  
 
 
 
 
4 ongoing phase III 
trials identified  
 
approved by both 
the EMA and the 
FDA 
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The median PFS was 5.5 months in the placebo group and was not reached 
in the idelalisib group. At 24 weeks, the PFS rate was 93% in the idelalisib 
group compared to 46% in the placebo group. The OS rate was 92% 
(idelalisib group) versus 80% (placebo group) at 12 months; median dura-
tion of OS also was not reached in either of the two treatment arms. ORR 
was 81% in the idelalisib group compared to 13% in the placebo group. The 
proportion of patients who had lymphadenopathy reduction of 50% or more 
was significantly higher in the idelalisib group than in the placebo group.  
An important finding of this trial was the treatment effect of idelalisib plus 
rituximab combination therapy on the pre-specified subgroups: the results 
in patients with genetic factors including 17p deletion, TP53 mutation or 
unmutated IGHV were superior to rituximab monotherapy [18]. As patients 
with these genetic lesions have a very poor outcome anyway and no uniform 
regimen for their optimal therapy exists, targeting the B-cell receptor signal-
ling pathway may yield better outcomes [23].  
The idelalisib-associated lymphocytosis showed a peak at weeks 2 and van-
ished at week 12 in the idelalisib group while starting to increase at week 24 
in the placebo group [18]. Appointed as a single agent, idelalisib mobilises 
malignant cells from tissues into peripheral blood where they may be more 
responsive to combination therapy [24].The mechanism of malignant B-cell 
release leads to a period of transient lymphocytosis that can be shortened by 
the addition of rituximab [25]. When lymphocytosis occurs during idelalisib 
treatment and there is no other evidence on disease progression (PD), the 
therapy should be continued until other definitive symptoms of PD appear 
[26]. 
At least one AE occurred in 90% of patients in each group, but most of them 
were grade 2 or lower. Most common AEs were pyrexia, fatigue, nausea, 
chills and diarrhoea in the idelalisib group, and infusion-related reactions, 
fatigue, cough, nausea and dyspnoea in the placebo group. 40% of patients 
in the idelalisib group and 35% of placebo group patients had at least one 
serious AE; most frequently were pneumonia, pyrexia and febrile neutro-
penia. Nonetheless, only 8% of patients in the idelalisib group and 10% of 
patients in the placebo group discontinued study treatment due to AEs.  
The trial was stopped early as a result of meeting its efficacy endpoints at 
the first interim data analysis. Patients from the placebo group were then of-
fered therapy with idelalisib [27, 28]. The early termination of the study 
caused a lack of data in long-term efficacy (median duration of exposure was 
about 5 months). Thus, further follow-up of the study population is re-
quired, especially because long treatment duration is expected in clinical 
practice [19]. In terms of safety, the potential occurrence of late side effects 
needs to be evaluated [29]. The idelalisib extension study (NCT01539291) 
may provide further information in this regard. 
For patients with relapsed CLL who are not eligible for intensive cytotoxic 
therapy (due to older age or comorbidities), chlorambucil (+/- rituximab), 
bendamustine (+/- rituximab) or dose-reduced FCR provide options [1]. 
Therefore the question is whether rituximab in addition to placebo is a suit-
able comparator, especially since rituximab alone is not licensed in Europe 
for the treatment of CLL. Despite this, rituximab-only treatment is an op-
tion frequently used in clinical practice for patients truly ineligible for 
chemotherapy. It remains unknown whether the included patients were in-
deed ineligible for further chemotherapy as a proper definition for these pa-
tients is not available [19]. However, the criteria applied for including 
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chemotherapy-ineligible patients in the phase III trial, i.e. severe myelosup-
pression from previous chemotherapy, reduced kidney function, or a CIRS 
score of more than 6 for non-CLL-related coexisting illnesses, are based on 
the suggestion of the German Leukaemia Study Group. 
Over the past few years, a number of novel agents were evaluated for the 
treatment of CLL, including ibrutinib, ofatumumab or alemtuzumab, as 
combination regimens or as single agents. Idelalisib is already the second 
kinase inhibitor specifically targeting CLL cells; recently, ibrutinib (Imbru-
vica®) has been approved by the EMA and the FDA for the treatment of pa-
tients with CLL who have received at least one prior therapy or as first-
line treatment in the presence of 17p deletion or TP53 mutation in pa-
tients unsuitable for chemoimmunotherapy. The approval decision was 
based on the results of the RESONATE trial, comparing ibrutinib versus 
ofatumumab in 391 pretreated CLL patients. In this study, patients were at 
a median age of 67 years and 32% of them had a CIRS score of more than 6 
[30]. In the idelalisib trial, patients had a median age of 71 years and 85% of 
them had a CIRS score of more than 6 and may thus be more representative 
of the potential target group. However, the direct comparison of idelalisib 
with ibrutinib may yield information as to which drug the patients benefit 
from the most. Further drugs in development are alvocidib, dinaciclib and 
duvelisib, all targeting CLL cell survival pathways [6].  
Both idelalisib and ibrutinib were granted marketing authorisation by the 
EMA and the FDA. One package ibrutinib containing 90 tablets at 140 mg 
costs € 6,598 which correspond to the monthly treatment costs assuming the 
administration of the recommended dose of 420 mg once daily [22]. Thus, 
the price for idelalisib is currently lower than for (single-agent) ibrutinib. 
However, for idelalisib in combination with rituximab (or other cancer 
treatments), costs exceed those for ibrutinib single-agent therapy. Addition-
ally, in contrast to ibrutinib, idelalisib contains a boxed warning on side ef-
fects such as colitis, lung inflammation and potential fatal liver problems, 
which may influence the drug’s success on the market [31]. An aspect that 
needs resolving with regard to both drugs is the development of resistance. 
There is evidence that intervening in the PI3K pathway could lead to drug 
resistance by up-regulation or activation of other PI3K isoforms [32]. 
Opinions concerning incorporating idelalisib in the complex treatment of 
CLL are currently diverging: on the one hand, the majority of CLL patients 
may potentially be spared toxic chemotherapy, on the other hand, chemo-
therapy combined with targeted therapies may be practicable in patients di-
agnosed in middle age or younger [27]. Choosing the appropriate therapy for 
elderly patients with CLL is an individual decision, considering the stage of 
the disease and risk factors as well as the patient’s physical condition and 
drug tolerability [33]. Possibly, the final results of the HRQL measurements 
(information currently only available as abstract publication) will contribute 
to guiding treatment decisions. 
The introduction of novel agents has influenced the management of high-
risk CLL, challenging the indication and timing of allogeneic haematopoiet-
ic stem cell transplantation (HSCT). For fit patients with high-risk CLL, 
HSCT has been considered as the treatment of choice, representing the only 
modality with documented curative potential in CLL. In contrast, both 
treatment-related mortality and morbidity are likely to be significantly low-
er with BCR-signal inhibitors/BCL2 antagonists as compared with HSCT 
(although more information is needed at that point). However, there is no 
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long-term data available on the efficacy of these novel agents. Hence, the 
HSCT option should be included in a treatment decision process [34]. 
In conclusion, combination therapy of idelalisib and rituximab offers a new 
treatment option for patients with relapsed CLL who are ineligible for cyto-
toxic therapy; particularly for those with genetic factors including 17p dele-
tion, TP53 mutation or unmutated IGHV. Nevertheless, further trials are 
needed to evaluate efficacy and safety in the long-term use of idelalisib, as 
well as the important issue of potential idelalisib resistance. 
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